Please login to the form below

Not currently logged in
Email:
Password:

ACT therapy

This page shows the latest ACT therapy news and features for those working in and with pharma, biotech and healthcare.

ACT immunotherapy cures terminal breast cancer patient

ACT immunotherapy cures terminal breast cancer patient

body - a “complete, durable regression” in the words of the scientists that developed the therapy. ... The ACT approach used by the researchers differs a little from chimeric antigen receptor T cell or CAR-T therapy, which have been approved for use

Latest news

  • Pipeline: Major depressive disorder therapeutics Pipeline: Major depressive disorder therapeutics

    ALKS 5461 is being developed as a once-daily therapy administered as a sublingual tablet. ... Brexpiprazole is a dopamine D2 partial agonist being developed as an oral adjunctive therapy.

  • Novartis to expand SMS for Life approach across Africa Novartis to expand SMS for Life approach across Africa

    In Tanzania, stock-outs of antimalarial treatment (Novartis' fixed-dose artemisinin-based combination therapy, or ACT, and quinine injectables) dropped from 79 per cent to less than 26 per cent in ... 2010 following the programme's debut, and the number

  • IQWiG knocks back Almirall's Eklira IQWiG knocks back Almirall's Eklira

    No proof of an added benefit of aclidinium bromide compared with the appropriate comparator therapy (ACT) can be inferred from the data in the drug manufacturer's dossier,” it concluded.

  • Novartis compounds treat malaria in blood and liver

    use. Moreover, there is a critical need for new malaria drugs in the face of emerging resistance even to the most effective artemisinin-based combination therapy (ACT) which was first encountered

  • Endo abuse-resistant pain drug rejected

    The drug was granted a priority review last year. Under the programme, which is reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy ... exists, the FDA aims to act on a new drug application (NDA)

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • The Holistic Approach to Market Access

    These individuals are highly trained in therapy and product science and should have either a PhD in research or medical or a pharmacy background. ... Though the educational material must be unbiased toward a specific product, when well developed the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics